They do not claim to affect GLP-1 levels
Individual Response Some patients respond well to lower doses, keeping costs at the lower end of our range
The dataset connects claims, labs and EHR, including physician notes to analyse: Who meets drug label or payer criteria based on actual BMI and comorbidities How titration and dosing progress in real-world care What metabolic outcomes patients achieve over time Which safety signals, such as liver or renal changes, emerge across populations Why patients discontinue or switch treatments, as documented in notes See real-world GLP-1 evidence in action Register for our webinar where we dive deeper into GLP-1 real-world evidence
Collectively, these results suggest that CD36 expression could explain the sensitivity of SUM-159 towards PA-induced ferroptosis in contrast to MCF-7
Jurkov, M., Danihel, , Polk, & Varga, I